News & Updates

The Global IDMP Working Group (GIDWG), is pleased to invite you to an online public meeting, streaming live from the European Medicines Agency (EMA) on Friday 3th October 2025 at 12:30 to 14:00 CEST via Zoom.

This year’s GIDWG Stakeholder Public Meeting will present important updates and insights from the Global IDMP Working Group. The co-chairs will highlight  key takeaways from the recent technical meeting, followed by contributions from GIDWG members  showcasing their involvement in IDMP and use case opportunities for Global PhPID Services

All interested stakeholders are welcome to attend the meeting and engage with this pivotal effort to strengthen global medicinal product data standards.

To register, please visit https://who-umc-org.zoom.us/webinar/register/WN_XTv5y_HpSUmDya9Z5TwodA

Our past conferences have been full of valuable information and great networking opportunities. We expect this year to be the same. Welcome to our 4th Global IDMP Working Group (GIDWG) Stakeholder Meeting, planned for the third week of September 2024, hosted by the Brazilian Health Regulatory Agency (Anvisa) in Brazil.

UPDATE: Thank you to everyone who attended the 4th GIDWG Technical and Stakeholder Meeting for making it such a success. It provided an excellent platform to further our shared vision of global IDMP implementation.

Presentations materials:

Testing of use cases for PhPID operating model

PURPOSE

To test the framework, including business rules, best practices, software, and operating model, for global IDMP implementation and maintenance of global identifiers for marketed products.

SCOPE

• Validate and generate PhPIDs for medicinal products based on GIDWG/EWG Business Rules

• EDQM and non-EDQM countries

• Similar products from different countries

• Larger batches and smaller data sets for regulators  

• Test use cases for pharmacovigilance, drug shortages, and cross-border healthcare

STATUS

Completed

Global IDMP PhPID End-to-End Testing report, 5 December 2024

The IDMP standards aim to harmonise how pharmaceutical products and substances are described globally. But how will that benefit patients and who will make sure the standards are properly implemented? Uppsala Monitoring Centre’s Malin Fladvad and Olle Lagerlund discuss the advantages and challenges of this global standardisation effort in the Drug Safety Matters podcast.